Lin et al. showed that third-generation EGFR CAR T cells effectively inhibited triple-negative breast cancer with limited cytotoxicity to normal breast epithelial cells or estrogen receptor-positive breast cancer cells in vitro, and they performed in vivo experiments. Here, EGFR is linked to triple-negative breast carcinoma.